Matthew Zuga
2022
In 2022, Matthew Zuga earned a total compensation of $1.2M as Chief Financial Officer and Chief Business Officer at Acumen Pharmaceuticals, a 53% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $163,148 |
|---|---|
| Option Awards | $580,500 |
| Salary | $429,836 |
| Other | $15,302 |
| Total | $1,188,786 |
Zuga received $580.5K in option awards, accounting for 49% of the total pay in 2022.
Zuga also received $163.1K in non-equity incentive plan, $429.8K in salary and $15.3K in other compensation.
Rankings
In 2022, Matthew Zuga's compensation ranked 2,700th out of 5,753 executives tracked by ExecPay. In other words, Zuga earned more than 53.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,700 out of 5,753 | 53rd |
Division Manufacturing | 1,501 out of 3,133 | 52nd |
Major group Chemicals And Allied Products | 691 out of 1,419 | 51st |
Industry group Drugs | 644 out of 1,320 | 51st |
Industry Biological Products, Except Diagnostic Substances | 157 out of 291 | 46th |
Source: SEC filing on April 27, 2023.
Zuga's colleagues
We found two more compensation records of executives who worked with Matthew Zuga at Acumen Pharmaceuticals in 2022.